Open-label Extension to Protocol 1042-0500

PHASE2TerminatedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

March 31, 2009

Study Completion Date

March 31, 2009

Conditions
Infantile Spasms
Interventions
DRUG

Ganaxolone

Trial Locations (14)

10467

Montefiore Medical Center- Albert Einstein College of Medicine, The Bronx

20010

Children's National Medical Center, Washington D.C.

23298

Virginia Commonwealth University Health Systems, Richmond

32504

Child Neurology Center of Nrothwest Florida, P.A., Pensacola

33155

Miami Children's Hospital, The Brain Institute, Miami

38105

Le Bonheur Children's Medical Center, Memphis

53201

Children's Hospital of Wisconsin, Milwaukee

55102

Minnesota Epilepsy Group, P.A., Saint Paul

60637

University of Chicago Comer Children's Hospital, Chicago

75230

Dallas Pediatric Neurology Associates, Dallas

77030

Texas Children's Hospital, Houston

90027

Children's Hospital of Los Angeles, Los Angeles

90095

Mattel Children's Hospital at UCLA, Los Angeles

98105

Children's Hospital and Regional Medical Center, Seattle

Sponsors
All Listed Sponsors
lead

Marinus Pharmaceuticals

INDUSTRY

NCT00442104 - Open-label Extension to Protocol 1042-0500 | Biotech Hunter | Biotech Hunter